This occurs for three reasons: traditional Medicare requires three separate insurance plans for comprehensive coverage; traditional Medicare drug plans are required to community rate, without adequate risk adjustment; and pharmacy benefit managers (PBMs) are able to calculate patients’ coinsurance based on list prices, rather than on the actual discounted prices the PBM pays the manufacturers. In addition, beneficiaries in all Medicare plans will pay more for drugs and drug insurance because the IRA removes more than $300 billion of government funding from Medicare Part D over 10 years—leaving the market with no alternative but to shift costs to beneficiaries. More.
